Wall Street analysts expect Aphria Inc (NYSE:APHA) to announce $58.04 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aphria’s earnings, with estimates ranging from $57.80 million to $58.28 million. Aphria posted sales of $9.36 million in the same quarter last year, which suggests a positive year-over-year growth rate of 520.1%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 7th.
According to Zacks, analysts expect that Aphria will report full year sales of $142.00 million for the current financial year, with estimates ranging from $102.32 million to $169.35 million. For the next financial year, analysts expect that the business will post sales of $501.60 million, with estimates ranging from $402.25 million to $676.13 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Aphria.
Several analysts have issued reports on the company. Clarus Securities assumed coverage on Aphria in a report on Tuesday. They set a “buy” rating and a $22.75 price target for the company. CIBC assumed coverage on Aphria in a report on Friday, January 18th. They set a “neutral” rating for the company. Zacks Investment Research lowered Aphria from a “hold” rating to a “sell” rating in a report on Friday. Seaport Global Securities assumed coverage on Aphria in a report on Thursday, February 21st. They set a “buy” rating and a $18.00 price target for the company. Finally, ValuEngine raised Aphria from a “hold” rating to a “buy” rating in a report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $15.69.
NYSE:APHA traded down $0.17 during mid-day trading on Monday, hitting $7.65. 10,335,052 shares of the company traded hands, compared to its average volume of 6,846,421. Aphria has a one year low of $3.75 and a one year high of $16.86. The firm has a market capitalization of $1.92 billion, a PE ratio of 54.64 and a beta of 4.08.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. bought a new position in shares of Aphria in the fourth quarter worth about $28,000. CIBC Asset Management Inc bought a new position in shares of Aphria in the fourth quarter worth about $671,000. Toronto Dominion Bank bought a new position in shares of Aphria in the fourth quarter worth about $723,000. JW Asset Management LLC bought a new position in shares of Aphria in the fourth quarter worth about $117,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Aphria in the fourth quarter worth about $74,000. 10.39% of the stock is owned by hedge funds and other institutional investors.
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Featured Story: What type of investment options does a Roth IRA provide?
Get a free copy of the Zacks research report on Aphria (APHA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.